All > Dbs > Ocd

SEEG Guided DBS ON-OFF (Stimulation-Sham) for Obsessive-Compulsive Disorder

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Obsessive-Compulsive DisorderPMT Stereoencephalography (SEEG) - Device
Eligibility
22 - 65
All Sexes
What conditions do you have?
Select

Study Summary

This is a dual-site, double-blinded, randomized, crossover study design for SEEG-guided 4-lead DBS for treatment-refractory OCD, followed by open label stimulation for an additional 6 months. The study will be conducted in 3 stages: Stage 1 will consist of SEEG brain mapping and optimization of stimulation parameters. Stage 2 will consist of DBS surgery and further optimization of stimulation parameters. Stage 3 will be randomized, crossover treatment, followed by open label treatment.

Eligible Conditions
  • Obsessive-Compulsive Disorder

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

2
Tight Pressure Management with etomidate induction
2
Pembrolizumab with Exablate BBBD
1
Canakinumab

Study Objectives

6 Primary · 0 Secondary · Reporting Duration: Approximately 4 years

14 days
Primary Feasibility Endpoint #1 - OCD Relevant Network
Primary Feasibility Endpoint #2 - Stimulation Target That Acutely Improves OCD Symptoms
Approximately 4 years
Primary Safety Endpoint - Serious Adverse Events
Approximately 60 weeks
Primary Feasibility Endpoint #4 - Acute Symptomatic Improvement
Day 14
Primary Feasibility Endpoint #3 - Willingness to Continue with DBS Stage 2
Up to 24 weeks
Primary Efficacy Endpoint - Treatment Response

Trial Safety

Safety Progress

1 of 3

Similar Trials

3
Tight Pressure Management with etomidate induction
3
Pembrolizumab with Exablate BBBD
2
Canakinumab

Trial Design

2 Treatment Groups

SEEG Guided DBS ON-OFF (Stimulation-Sham)
1 of 2
SEEG Guided DBS OFF-ON (Sham-Stimulation)
1 of 2

Experimental Treatment

Non-Treatment Group

10 Total Participants · 2 Treatment Groups

Primary Treatment: SEEG Guided DBS ON-OFF (Stimulation-Sham) · Has Placebo Group · N/A

SEEG Guided DBS ON-OFF (Stimulation-Sham)Experimental Group · 2 Interventions: PMT Stereoencephalography (SEEG), Vercise Genus™ Deep Brain Stimulation (DBS) System · Intervention Types: Device, Device
SEEG Guided DBS OFF-ON (Sham-Stimulation)ShamComparator Group · 2 Interventions: PMT Stereoencephalography (SEEG), Vercise Genus™ Deep Brain Stimulation (DBS) System · Intervention Types: Device, Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: approximately 4 years

Who is running the clinical trial?

Casey H. Halpern, M.D.Lead Sponsor
University of California, San FranciscoOTHER
2,283 Previous Clinical Trials
11,577,644 Total Patients Enrolled

Eligibility Criteria

Age 22 - 65 · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are at least 22 years old and at least 65 years old.
You have OCD, which is a chronic mental disorder that causes excessive thoughts, feelings, and behaviors.
You have a time-consuming obsession or compulsion that takes more than one hour a day or causes clinically significant distress or impairment in social, occupational, or other important areas of functioning.
You have obsessive-compulsive symptoms that are not attributable to the physiological effects of a substance (e.g.
You have a history of the following treatments, based on information from any of the following: (a) the current treating physician and/or psychologist; (b) medical records or other forms of communication from previous healthcare providers; and (c) pharmacy records, as determined by the Principal Investigator.
The medication was given for a minimum of 1 month and a maximum of 6 months.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top